Fortunately, therapeutic strategies for RCC have rapidly evolved throughout the last decade, among which ICIs or TKIs alone or in combination have been regarded as the standard treatment in advanced RCC (26); however, a moderate tumor mutation burden (TMB) and an inverse correlation between infiltrating CD8+ T cells and prognosis of patients have limited the further utility of ICIs (27, 28). The gene discussed is CD8A; the disease is neoplasm.